PeerVoice Oncology & Haematology Audio PeerVoice

Visit https://www.peervoice.com/YQM860 to view the entire programme with slides. After completing “Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma”, participants will be able to: Recall safety and efficacy data evaluating the combination of an antibody-drug conjugate (ADC) plus an immune checkpoint inhibitor (ICI) for the first-line management of locally advanced/metastatic urothelial carcinoma (la/mUC); Apply recently updated guideline recommendations regarding first-line management of patients with la/mUC; and Recognise adverse events associated with the combination of an ADC and ICI for the management of la/mUC.

Visit https://www.peervoice.com/XCA860 to view the entire programme with slides. After completing “David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey”, participants will be able to: Identify the most appropriate modalities for, and timing of, molecular testing to facilitate use of targeted therapies for cholangiocarcinoma (CCA); Design comprehensive, appropriately sequenced treatment regimens for CCA, which integrate targeted therapies in patients with actionable alterations; and Monitor and manage the safety and effectiveness of targeted treatment regimens for CCA.

Visit https://www.peervoice.com/HEG860 to view the entire programme with slides. After completing “María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance”, participants will be able to: Recall safety and efficacy data from clinical trials evaluating BCMA-directed therapies for the management of relapsed/refractory multiple myeloma; and Assess the potential clinical impact of these data, including patient populations included in trials and how these relate to real-world patients.

Visit https://www.peervoice.com/HEF860 to view the entire programme with slides. After completing “Shaji Kumar, MD - Age Is More Than Just a Number: Tailoring Treatment Across the Multiple Myeloma Journey for Our Older and/or Unfit Patients”, participants will be able to: Recognise the heterogeneous issues faced by people with multiple myeloma (MM) who are of advanced age or may have other factors that render them unfit for conventional therapy; Assess the clinical relevance of trial data and real-world evidence assessing different treatment approaches in the management of MM in older patients; and Formulate individualised management plans for patients considered elderly and/or unfit for conventional myeloma treatment approaches.

Visit https://www.peervoice.com/QHY860 to view the entire programme with slides. After completing “Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC”, participants will be able to: A key challenge is that physicians cannot simply order a “MET test”; different tests must be used to detect the different alterations;; Exon 14 skipping mutations, amplification, and fusion can be detected via DNA or RNA-based next-generation sequencing (NGS);; Amplification and fusion may also be detected by fluorescence in situ hybridization (FISH);; and Overexpression is detected via immunohistochemistry (IHC)..

Visit https://www.peervoice.com/HZH860 to view the entire programme with slides. After completing “Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents”, participants will be able to: Recall available safety and efficacy data evaluating the use of BTK inhibitors in the management of chronic lymphocytic leukaemia (CLL); and Implement evidence-based best practices for the management of CLL with BTK inhibitors, including sequencing alongside other agents (such as BCL-2 inhibitors) and switching between BTK inhibitors following adverse event (AE)-related discontinuation.